Please assess the completion status of the following clinical trial:

Trial Title: Gastroesophageal Reflux Treatment in Scleroderma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 1 study for evaluation the prevalence of omeprazole resistant-GERD~Inclusion criteria:~1. SSc patients aged between 18 and 65 years.~2. Clinically diagnosed as GERD and GERD-questionnaire score \>3~3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks before baseline evaluation~Exclusion criteria:~1. Pregnancy or lactation~2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe erosive esophagitis~3. Present of Barrett's esophagus~4. Bedridden and confined to no self-care~5. Evidence of active malignant disease~6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or renal diseases~7. Present of active infection that needs systemic antibiotic~8. Allergic history of omeprazole~9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate~Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 2 study.~Inclusion criteria:~1. SSc patients who completed the phase 1 study.~2. The subjects were defined as PPI-resistance.~3. The subject must be willing to continue phase 2 study.~Exclusion criteria:~1. Pregnancy~2. Present of uncontrolled or severe medical problems~3. Present of active infection~4. Allergic history of alginic acid or domperidone~5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate~6. Chewing difficulty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omeprazole plus alginic acid and placebo of domperidone (Type: EXPERIMENTAL): None
- Omeprazole plus domperidone and placebo of alginic acid (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).